Big pharma sees opportunity in Russia

Russian drug manufacturing is getting a shot in the arm as big pharma makes a play to become entrenched in-country. Investing in local drugmakers provides a convenient workaround to import complexities, reports

Building and buying facilities are the chief means. Among those in on the secret: Nycomed, Novo Nordisk, AstraZeneca and Novartis, says Reuters, along with a half-dozen others are reportedly considering the idea. They are after a piece of the projected 2010 mid-double-digit percentage growth of the Russian pharma market, an appealing contrast to the global projection of 4 percent to 6 percent.

The Association of International Pharmaceutical Manufacturers in Russia expects global drugmakers to drop a combined $1 billion on setting up local production.  

- see the story
- here's the Reuters rundown of players

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.